Stifel Upgrades Puma Biotechnology (PBYI) to Buy After Neratinib NDA Accepted

September 20, 2016 4:50 PM EDT Send to a Friend
Stifel upgraded Puma Biotechnology (NYSE: PBYI) from Hold to Buy with a price target of $88.00 (from $61.00) after the ...

To continue reading this article and more like it please sign-in or join today (FREE!)

Member Login